Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics Rolls Out Phase Two of DiscoveryCenter for Schering

NEW YORK, Oct. 15 – NetGenics has completed the second phase of its DiscoveryCenter database build-out for Schering and its US subsidiary Berlex Laboratories, the company said on Monday.

The three-part implementation, scheduled to close around February 2002, provides a single point of access to curated and annotated gene-sequence and -expression data for Schering’s R&D scientists, according to NetGenics CEO Manual Glynias. 

The multiyear deal, which NetGenics won last June, is a “multimillion dollar” contract and includes a yearly licensing and maintenance fee beyond the completion of the project, Glynias told GenomeWeb

The system built for Berlin-based Schering includes technology from NetGenics’ Component Library and IBM's DiscoveryLink, which NetGenics is authorized to distribute as part of an agreement made with the computer giant in April. 

While parts of the custom-built system are proprietary to Schering, the core can be sold to other companies, said Glynias, who sees the product as “the next step beyond Lion’s SRS.”

In addition to providing upgrades to its DiscoveryCenter, NetGenics is looking to develop a product to integrate gene-expression data with chemo-informatics data, said Glynias, who said that such a product would need to follow the DiscoveryCenter-Schering development model. 

“To succeed in a chemo-informatics phase, we need to do the exact same thing: looking for a partner in chemo-informatics and a client, either big pharma or a biotech company,” he explained.

In September, NetGenics, based in Cleveland, withdrew its proposed $60 million to $70 million initial public offering. Glynias said the company would wait for the market to improve before considering another IPO.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.